Neunteufel W, Bieglmayer C, Breitenecker G
2nd Department of Obstetrics and Gynecology, University of Vienna, Wien, Austria.
Arch Gynecol Obstet. 1988;244(1):47-52. doi: 10.1007/BF00931402.
Samples of 40 endometrial carcinomas were examined by immunohistochemical methods for CA19-9, CA125 and CEA. CA19-9 was detected in 93%, CA125 in 65% and CEA in 58%. CA19-9 was detected in more than 50% of tumor cells in 14 cases and the same was true for CA125 in six cases. In no tumor was CEA found in more than half the cells. The distribution of CA125 and CEA was markedly more heterogenous than that of CA19-9. There was no statistically significant correlation between immunohistochemical markers on the one hand, and estrogen and progesterone receptor content on the other. A correlation between histological grading and marker detection was only found for CA19-9. CA19-9 was detected in almost all endometrial carcinoma samples, and was the most homogenously distributed. This makes CA19-9 a possibly useful tumor marker for endometrial carcinoma.
采用免疫组化方法对40例子宫内膜癌样本进行CA19-9、CA125和癌胚抗原（CEA）检测。93%的样本检测到CA19-9，65%检测到CA125，58%检测到CEA。14例样本中超过50%的肿瘤细胞检测到CA19-9，6例样本中超过50%的肿瘤细胞检测到CA125。无一例样本中超过半数细胞检测到CEA。CA125和CEA的分布明显比CA19-9更不均匀。一方面免疫组化标志物与另一方面雌激素和孕激素受体含量之间无统计学显著相关性。仅发现组织学分级与CA19-9标志物检测之间存在相关性。几乎所有子宫内膜癌样本均检测到CA19-9，且其分布最为均匀。这使得CA19-9可能成为子宫内膜癌有用的肿瘤标志物。
